Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Phase 4

Completed

• Conditions: Coronary Arteriosclerosis

• Registration Number: NCT00129038
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone

Detailed Description

Not available

Study Timeline

• Study Start: 2004-04
• Study First Submitted: 2005-08-10
• Study First Submitted QC: 2005-08-10
• Study First Posted: 2005-08-11
• Primary Completion: 2007-01
• Status Verified: 2013-10
• Last Update Submitted: 2013-10-28
• Last Update Posted: 2013-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Cardiovascular disease (including history of stroke or transient ischaemic attack)
• Documented evidence of resistance to aspirin
• Capable of comprehending and communicating effectively with the investigator and staff and of providing informed consent.
• Willing to give informed consent prior to participation in the trial.

Read More

Exclusion Criteria

• Any clinically significant condition other than cardiovascular disease.
• Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings.
• Use of dipyridamole, clopidogrel, ticlopidine or any non-steroidal anti-inflammatory agent (NSAID)(including COX-2 inhibitors) during the two weeks before randomisation and during the trial.
• Active peptic ulceration or history of peptic ulcer disease.
• Known history of or suspected hypersensitivity to dipyridamole, aspirin, any NSAID or any other component of the test drugs.
• History of any bleeding disorder.
• History of cerebral haemorrhage.
• Resting seated blood pressure less than 90/60mmHg.
• Participation in any drug clinical trial within sixteen weeks prior to the start of the trial.
• Any indication of current or previous abuse of alcohol, solvents or drugs.
• Asthma.
• Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g. oral contraceptives, intrauterine devices or surgically sterile).
• Previous participation in the randomisation phase of this clinical trial.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
platelet aggregation in response to arachidonic acid	baseline, day 14, day 30 of each period

Secondary Outcome Measures

Name	Time	Method
flow cytometry measurements from bleeding time samples	day 30 of each period]
coagulation markers F1.2 and fibrinopeptide A (in bleeding time samples)	day 30 of each period
pulse rate and blood pressure	baseline, day 14, day 30 of each period
platelet aggregation in response to epinephrine, adenosine diphosphate (ADP) and collagen	baseline, day 14, day 30 of each period
serum thromboxane B2	baseline, day 14, day 30 of each period
urinary 11-dehydro-thromboxane B2	baseline, day 30 of each period
flow cytometry measurements of platelet receptors in blood samples	baseline, day 14, day 30 of each period
6-keto-prostaglandin F1α (in bleeding time samples)	day 30 of each period
thromboxane B2 (in bleeding time samples)	day 30 of each period
urinary 2,3,-dinor-6-keto-prostaglandin F1α	baseline, day 30 of each period
plasma CD40L	baseline, day 14, day 30 of each period
bleeding time	day 30 of each period

Trial Locations

Locations (2)

9.169.02 St. James' Hospital; 🇮🇪 Dublin 8, Ireland

9.169.01 Dept of Clinical Pharmacology; 🇮🇪 Dublin 9, Ireland